Vice Governor Zhang Shizhen investigated the construction and advancement of Lanbai Science and Technology Innovation reform Pilot Zone - to Kangyuxin biological guidance work
Zhang Shizhen visited our company, Wang Youwei, general manager in charge of Baiyin Kang Yuxin Biology, made a comprehensive introduction, provincial leaders detailed understanding of enterprise scientific and technological innovation and transformation of results, production and operation, research and development investment, talent introduction, etc., on-site to help enterprises find shortcomings, analyze reasons, propose countermeasures, and coordinate solutions. He stressed that relevant departments at all levels should firmly establish a new development concept, unswervingly embed strong science and technology actions deeply into strong industries, strong provincial capitals, and strong county actions, further strengthen responsibility, initiative, and forward service, increase the help and guidance of key industrial projects, and play the two cards of "independent innovation" and "first try". Maximize the great potential of science and technology as the first productive force and innovation as the first driving force, do everything possible to enhance the demonstration and leading efficiency of chain enterprises, and through innovative thinking and practice, strive to overcome the "hard bones" in the development of resource recycling and reuse, and promote the realization of green development and high-quality development with scientific and technological innovation.
Kohn & Shawn Pharmatech
Kangyuxin Biotechnology Co., Ltd. was established in October 2013, specializing in the research and development, production, sales and related service technology development of pyrazine intermediates and process libraries. Kangyuxin has more than 2,000 square meters of standardized laboratories, with an output value of more than 80 million yuan in 2022. The core technology of pyrazine derivatives of Kangyuxin ranks the leading level in China, and the varieties and orders of pyrazine series products are ranked first in the domestic industry. Kangyuxin has an experienced and high-quality drug process research and development team, which can realize the research and development and process production from lead compounds to clinical batch apis. Kangyuxin Drug Quality research team can provide effective data and method validation for drug registration and research.
The company was supported by the innovation Fund of Gansu Province in 2016, and was identified as the first batch of provincial science and technology innovation enterprises by the Department of Science and Technology of Gansu Province, and has been supported by the science and technology innovation Fund of Lanzhou and Baiyin for many times. Wang Youwei, the founder of the company, was named "One hundred innovative and entrepreneurial models in Lanzhou City" in 2015. Kangyuxin, as the first domestic enterprise to develop a broad spectrum antiviral new drug "Fapiravir", was shortlisted in the eighth batch of key protection enterprises for epidemic prevention materials in Gansu Province. Kangyuxin won the Excellence Award of the 10th China Innovation and Entrepreneurship Competition National Biomedical Industry Competition in 2021 (the second place in the group), and the second place in the Gansu Division of the 10th China Innovation and Entrepreneurship Competition. Won the first prize in the Northwest region of the 2020 "Guotong Cup" Lanzhou University Global Alumni Entrepreneurship Competition, and the first prize of the Baiyin Double Innovation Competition for two consecutive years in 2020 and 2021. In 2022, it will be evaluated as a high-tech enterprise and a specialized and special new enterprise.
